Deutsche Bank Keeps Their Hold Rating on AstraZeneca (AZN)
BMO Capital Maintains AstraZeneca(AZN.US) With Buy Rating, Cuts Target Price to $88
Leerink Partners Maintains AstraZeneca(AZN.US) With Buy Rating
Barclays Keeps Their Buy Rating on AstraZeneca (AZN)
AstraZeneca Raised to Buy From Hold by Intron Health
AstraZeneca (AZN) Gets a Hold From Jefferies
UBS Remains a Sell on AstraZeneca (AZN)
TD Cowen Maintains AstraZeneca(AZN.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: AstraZeneca (AZN) and Neurogene (NGNE)
BMO Capital Maintains AstraZeneca(AZN.US) With Buy Rating, Maintains Target Price $89
J.P. Morgan Keeps Their Buy Rating on AstraZeneca (AZN)
TD Cowen Maintains AstraZeneca(AZN.US) With Buy Rating
AstraZeneca Raised to Hold From Sell by Deutsche Bank
BofA Securities Maintains AstraZeneca(AZN.US) With Buy Rating
BMO Capital Maintains AstraZeneca(AZN.US) With Buy Rating, Maintains Target Price $89
AstraZeneca (AZN) Gets a Sell From Deutsche Bank
AstraZeneca's Promising Obesity Treatment Advances Justify Buy Rating: Analyst Report
UBS Reaffirms Their Sell Rating on AstraZeneca (AZN)
J.P. Morgan Remains a Buy on AstraZeneca (AZN)
Berenberg Bank Reaffirms Their Buy Rating on AstraZeneca (AZN)